These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34797350)

  • 1. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
    Xu H; Chai SS; Lv P; Wang JJ
    Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
    Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
    CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calponin 3 Acts as a Potential Diagnostic and Prognostic Marker and Promotes Glioma Cell Proliferation, Migration, and Invasion.
    Xie Y; Ding W; Xiang Y; Wang X; Yang J
    World Neurosurg; 2022 Sep; 165():e721-e731. PubMed ID: 35792226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
    Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
    Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
    Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
    Front Immunol; 2022; 13():810832. PubMed ID: 35265072
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
    Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
    Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.
    Zhou Y; Wang X; Huang X; Li XD; Cheng K; Yu H; Zhou YJ; Lv P; Jiang XB
    CNS Neurosci Ther; 2020 Mar; 26(3):309-318. PubMed ID: 31710183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
    Tian R; Li Y; Shu M
    Front Immunol; 2021; 12():797450. PubMed ID: 35069579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
    Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
    Front Immunol; 2022; 13():946692. PubMed ID: 35928818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment.
    Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z
    Front Immunol; 2021; 12():691811. PubMed ID: 34489938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
    He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
    Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
    Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
    Front Neurol; 2022; 13():977180. PubMed ID: 36353126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
    Yang G; Tang S; Zhang J; Qin L
    World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
    Qi Y; Chen D; Lu Q; Yao Y; Ji C
    Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.